Treatment of Hepatitis C in HIV-Infected Patients: Moving Towards an Era of All Oral Regimens

AIDS Patient Care and STDs

Volumn 29, Issue 6, 2015, Pages 329-337

  Chen, Ting Yi ^a   Jain, Mamta K ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASUNAPREVIR; BOCEPREVIR; DACLATASVIR; DASABUVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; ELBASVIR; FALDAPREVIR; GRAZOPREVIR; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; ANTIVIRAL AGENTS; INTERFERONS; RNA, VIRAL;

ARTICLE; CLINICAL TRIAL (TOPIC); FOOD AND DRUG ADMINISTRATION; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; BLOOD; COINFECTION; COMPLICATION; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HIV INFECTIONS; HUMANS; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; COINFECTION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERONS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 84930168855     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2014.0247     Document Type: Article

References (77)

1. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012;156:271-278.
2. Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007;146:87-95.
3. Schwarcz SK, Vu A, Hsu LC, Hessol NA. Changes in causes of death among persons with AIDS: San Francisco, California, 1996-2011. AIDS Patient Care STD 2014;28:517-523.
4. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-450.
5. Moreno A, Quereda C, Moreno L, et al. High rate of didanosine-related mitochondrial toxicity in HIV/HCVco-infected patients receiving ribavirin. Antivir Ther 2004;9:133-138.
6. Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat 2006;13:683-689.
7. IDSA/AASLD: Recommnedations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org 2014 (Last accessed April 2, 2015).
8. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879-1888.
9. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-1493.
10. FDA approved drug products: Ledipasvir and Sofosbuvir.
11. Townsend KOA, Nelson A, et al. High efficacy of sofosbuvir/ledipasvir for the treatment of HCV genotype 1 in patients co-infected with HIV on or off antiretroviral therapy: Results from the NIAID ERADICATE trial. The American Association for the Study of Liver Diseases, November 9-13, 2014, Boston, MA.
12. th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, May 19-21, 2014, Washington, DC.
13. FDA approved drug products: Sofosbuvir. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/204671s000lbl.pdf (Last accessed April 2, 2015).
14. FDA approved drug products: Simeprevir. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/205123s001lbl.pdf (Last accessed April 2, 2015).
15. FDA approved drug products: Telaprevir. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/201917s012lbl.pdf (Last accessed April 2, 2015).
16. FDA approved drug products: Boceprevir. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/202258s015lbl.pdf (Last accessed April 2, 2015).
17. Bifano M, Hwang C, Oosterhuis B, et al. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: Ritonavir-boosted atazanavir, efavirenz and tenofovir. Antivir Ther 2013;18:931-940.
18. st Conference On Retroviruses And Opportunistic Infections, March 3-6, 2014, Boston MA.
19. st Conference on Retroviruses and Opportunistic Infections, 2014, Boston MA.
20. st Conference on Retroviruses and Opportunistic Infections, March 3-6, 2014, Boston MA.
21. Ouwerkerk-Mahadevan S, Sekar V, Simion A, et al. The pharmacokinetic interactions of the HCV protease inhibitor simeprevir (TMC435) with HIV antiretroviral agents in healthy volunteers. 2012 Infectious Diseases Society of America (IDSA), October 17-21, 2012, San Diego.
22. th European AIDS Conference, October 16-19, 2013, Brussels, Belgium.
23. th International Workshop on Clinical Pharmacology of Hepatitis Therapy, June 26-27, 2013, Boston MA.
24. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: The COSMOS randomised study. Lancet 2014; 384:1756-1765.
25. th Annual Meeting of the American Association for the Study of Liver Diseases, November 1-5, 2013, Washington DC.
26. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1604-1614.
27. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1594-1603.
28. Wyles D, Sulkowski M, Eron J, et al. TURQUOISE-I: 94% SVR12 in HCV/HIV-1 co-infected patients treated with ABT-450/r/Ombitasvir, Dasabuvir and ribavirin. American Association for the Study of Liver Diseases, 2014, Boston, MA.
29. Manns M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014;384:414-426.
30. Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatmentnaive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014;384:403-413.
31. th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 1-5, 2013, Washington, DC.
32. Dieterich D, Rockstroh J, Orkin C, et al. Simeprevir (TMC435) plus PegIFN/Ribavirin in HCV genotype-1/HIV-1 co-infection (Study C212). March 3-6, 2014, Boston MA.
33. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-1887.
34. Rodriquez-Torres M, Rodriguez-Orengo J, Gaggar A, et al. Sofosbuvir and peginterferonn alfa-2a/ribavirin for treatment-naive genotype 1-4 HCV-infected patients who are co-infected with HIV. ID Week, October 2-6, 2013, 2013, San Francisco, CA.
35. Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV co-infection. JAMA 2014;312:353-361.
36. Rodriguez-Novoa S, Morello J, Gonzalez M, et al. Increase in serum bilirubin in HIV/hepatitis-C virus-co-infected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin. AIDS 2008;22:2535-2537.
37. Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: A randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013;13:597-605.
38. Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: A randomized trial. Ann Intern Med 2013;159:86-96.
39. th Conference on Retroviruses and Opportunistic Infections February 27-March 2, 2011, Boston MA.
40. Hulskotte EG, Feng HP, Xuan F, et al. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin Infect Dis 2013;56:718-726.
41. Garraffo R, Lavrut T, Chen S, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV, April 22-24, 2013, Amsterdam, Netherland.
42. Hammond KP, Wolfe P, Burton JR, Jr., et al. Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers. J Acquir Immune Defic Syndr 2013;62:67-73.
43. de Kanter CT, Blonk MI, Colbers AP, Schouwenberg BJ, Burger DM. Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir. Clin Infect Dis 2013;56:300-306.
44. th International HIV Clinical Pharmacology Workshop, April 22-24, 2013, Amsterdam, Netherland.
45. th Conference on Retroviruses and Opportunistic Infections. March 3-6, 2013, Atlanta GA.
46. Moreno A, Quereda C, Montes M, et al. Safe coadministration of raltegravir-based HAART in HIV-infected patients with HCV-cirrhosis receiving triple therapy with telaprevir or boceprevir. J Acquir Immune Defic Syndr 2012;61:e47-e49.
47. th International HIV Clinical Pharmacology Workshop, April 22-24, 2013, Amsterdam, Netherland.
48. Montes M, Nelson M, Girard P, et al. Telaprevir combination therapy in treatment-naïve and experienced patients co-infected with HCV and HIV (INSIGHT STUDY): Sustained virologic response at 12 weeks final analysis. The American Association for the Study of Liver Diseases, November 1-5, 2013, Boston, MA.
49. th Conference on Retroviruses and Opportunistic Infections, February 27-March 2, 2011, Boston, MA.
50. Henshaw J, Adiwijaya B, Adda N, et al. The pharmacokinetics of telaprevir and selected ART medications in HCV/HIV co-infected patients. ID Week, October 17-21, 2012, San Diego.
51. th European AIDS Conference (EACS), October 16-19, 2013, Brussels, Belgium.
52. th International Workshop on Clinical Pharmacology of HIV Therapy, April 16-18, 2012, Barcelona, Spain.
53. th Annual Meeting of the American Association for the Study of Liver Diseases, November 9-13, 2012, Boston MA.
54. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014.
55. th Conference on Retroviruses and Opportunistic Infections, March 5-8, 2012, Seattle, WA.
56. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211-221.
57. nd Conference on Retroviruses and Opportunistic Infections. February 23-26, 2015, Seattle, WA.
58. Manns MP, Vierling JM, Bacon BR, et al. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. Gastroenterology 2014;147:366-376.
59. Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of MK-5172 + MK8742 with or without RBV in HCV mono-infected and HIV/HCV co-infected treatmentnaive, non-cirrhotic patients with hepatitis C virus genotype 1 infection: The C-WORTHY study (Final results, Parts A and B). American Association for the Study of Liver Diseases, November 8-13, 2014, Boston, MA.
60. th Annual Meeting, November 1-5, 2013, Washington, DC.
61. th Annual Meeting of the European Association for the Study of the Liver, April 9-13, 2014, London, UK.
62. Dieterich D, Tural C, Nelson M, et al. Faldaprevir plus pegylated interferon α-2a/ribavirin in HIV/HCV co-infection: STARTVerso4. CROI 2014, Boston.
63. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370:1993-2001.
64. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867-1877.
65. st Conference on Retroviruses and Opportunistic Infections, March 3-6, 2014, Boston MA.
66. Lawitz E, Poordad F, Brainard DM, et al. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology 2015;61:769-775.
67. th Annual Meeting of the European Association for the Study of the Liver, April 9-13, 2014, London, UK.
68. Gane E, Hyland R, An D, et al. High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infection. American Association for the Study of Liver Diseases, 2014, Boston, MA.
69. Nelson DR, Cooper JN, Lalezari J, et al. All-oral 12-week combination treatmentwith daclatasvir and sofosbuvir in patients infected with HCV genotype 3: ALLY-3 phase 3 study. American Association for the Study of Liver Diseases, November 9-13, 2014, Boston, MA.
70. Pol S, Reddy R, Baykal T, et al. Interferon-free regimens of ombitasvir and ABT-450/r with or without ribavirin in patients with HCV genotype 4 infection: PERAL-I study results. American Association for the Study of Liver Diseases, 2014, Boston, MA.
71. Kapoor R, Kohli A, Sidharthan S, et al. Treatment of hepatitis C genotype 4 with ledipasvir and sofosbuvir for 12 weeks: Tesults fo the SYNDERGY trial. American Association for the Study of Liver Diseases, November 9-13, 2014, Boston, MA.
72. Ruane PJ, Ain D, Stryker R, et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol 2014; SO168-8278.
73. Wehmeyer MH, Eissing F, Jordan S, et al. Safety and efficacy of protease inhibitor based combination therapy in a single-center "real-life" cohort of 110 patients with chronic hepatitis C genotype 1 infection. BMC Gastroenterol 2014;14:87.
74. Mandorfer M, Payer BA, Niederecker A, et al. Therapeutic potential of and treatment with boceprevir/telaprevir-based triple-therapy in HIV/chronic hepatitis C co-infected patients in a real-world setting. AIDS Patient Care STDs 2014;28:221-227.
75. Dieterich D, Bacon B, Flamm S, et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network-Academic and community treatment of a real-world, heterogeneous population. American Association for the Study of Liver Diseases, November 9-13, 2014, Boston, MA.
76. Jensen DM, O'Leary J, Pockros P, et al. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: Realworld experience in a diverse, longitudinal observational cohort. American Association for the Study of Liver Diseases, November 9-13, 2014, Boston, MA.
77. Del Bello D, Bichoupan K, Yalamanchili R, et al. Realworld data on HIV positive patients with HCV genotype 1,2 and 3 on sofosbuvir-and simeprevir-containing regimens. American Association for the Study of Liver Diseases, November 9-13, 2014, Boston, MA.